Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Fineline Cube Aug 17, 2026
Company Deals

Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development

Fineline Cube Aug 14, 2026
Company Deals

ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions

Fineline Cube Aug 14, 2026
Company Deals

IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics – Adding PEBL‑Based CAR‑T Cell Therapy Platform for T‑Cell Malignancies

Fineline Cube Aug 14, 2026
Company Deals

Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide’s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal

Fineline Cube Aug 13, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Fineline Cube Aug 17, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

Fosun Pharmaceutical Secures Clinical Trial Approvals for VT-101 in China and the US

Fineline Cube Nov 20, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced receiving clinical trial approvals for...

Policy / Regulatory

National Reimbursement Drug List Negotiations and Bidding Process Conclude

Fineline Cube Nov 20, 2023

The on-site negotiation and bidding processes for the 2023 update to China’s National Reimbursement Drug...

Company Medical Device

Beijing Balance Medical Technology’s Transcatheter Aortic Valve System Accepted for NMPA Review

Fineline Cube Nov 20, 2023

China’s Beijing Balance Medical Technology Co., Ltd (SHA: 688198) has announced that the National Medical...

Company Deals

Amgen Partners with PostEra for Small-Molecule Drug Discovery Initiative

Fineline Cube Nov 20, 2023

Biopharmaceutical company Amgen (NASDAQ: AMGN) has entered into a drug discovery collaboration with US-based PostEra,...

Company Deals

Baheal Pharmaceutical Group Enters Commercialization Partnership with Guangdong Ruidio Technology

Fineline Cube Nov 20, 2023

China-based health services and distribution giant Baheal Pharmaceutical Group has struck a commercialization partnership with...

Company Drug

Pfizer and Astellas Pharma Secure FDA Approval for Xtandi in High-Risk Non-Metastatic Prostate Cancer

Fineline Cube Nov 20, 2023

Partners Pfizer (NYSE: PFE) and Astellas Pharma (TSE: 4503) last week received indication extension approval...

Company Drug

Yifan Pharmaceutical’s Subsidiary Receives FDA Approval for Ryzneuta (F-627)

Fineline Cube Nov 20, 2023

China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) has announced that its subsidiary, Evive Biotech Ltd.,...

Company Drug

AstraZeneca Receives FDA Approval for Truqap in HR-Positive, HER2-Negative Breast Cancer

Fineline Cube Nov 20, 2023

UK-based pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) announced last week that it has received regulatory...

Company Drug

Alphamab Oncology’s JSKN003 ADC: Promising Preliminary Data in Advanced Solid Tumors

Fineline Cube Nov 17, 2023

Alphamab Oncology (HKG: 9966) has released preliminary data from a Phase I clinical study on...

Policy / Regulatory

Final Results of China’s Round 9 Volume-Based Procurement Tender Announced

Fineline Cube Nov 17, 2023

The National Allied Procurement Office has released the finalized results and tender bid allocations for...

Company Drug

BMS’s Augtyro Receives FDA Approval for ROS1-Positive NSCLC

Fineline Cube Nov 17, 2023

The US Food and Drug Administration (FDA) has granted Bristol Myers Squibb (BMS, NYSE: BMY)...

Drug Policy / Regulatory

CDE Releases 76th Batch of Chemical Generic Reference Preparations

Fineline Cube Nov 17, 2023

The Center for Drug Evaluation (CDE) has released the 76th batch of chemical generic reference...

Company Drug

Yipinhong Pharmacy’s AR882 Shows Promise in Gout Treatment in Phase II Study

Fineline Cube Nov 17, 2023

China-based Yipinhong Pharmacy Co., Ltd (SHE: 300723) has announced positive data from a Phase II...

Company Drug

Easton Pharmaceutical Receives FDA Approval for Generic Nalmefene

Fineline Cube Nov 17, 2023

Chengdu-based Easton Pharmaceutical Co., Ltd (SHA: 688513) has announced receiving Abbreviated New Drug Application (ANDA)...

Deals R&D

University of Hong Kong to Host Infectious Disease Labs by UN’s Vaccine Institute and Cambridge University

Fineline Cube Nov 17, 2023

The University of Hong Kong (HKU) is poised to host new infectious disease laboratories established...

Company

BeiGene Ltd Opens Global Industrialization Base for Small-Molecule Drugs in Suzhou

Fineline Cube Nov 17, 2023

BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced the inauguration of its small-molecule...

Company Drug

Visen Pharmaceuticals Reports Positive Phase II Results for TransCon CNP in Achondroplasia

Fineline Cube Nov 17, 2023

Visen Pharmaceuticals, a joint venture between Denmark-based Ascendis Pharma A/S (NASDAQ: ASND) and Chinese healthcare...

Company Deals

Jiangxi Rimag Group Eyes Hong Kong IPO to Expand Medical Imaging Services

Fineline Cube Nov 17, 2023

Jiangxi Rimag Group Co., Ltd (HKG: 2522), a China-based medical imaging specialist, is planning an...

Company Drug

Vertex Pharmaceuticals and CRISPR Therapeutics Receive Conditional Approval for CRISPR Gene-Editing Therapy

Fineline Cube Nov 17, 2023

Vertex Pharmaceuticals (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) have received conditional approval from the...

Company Deals

Q32 Bio Reclaims Development Rights to Anti-IL-7Rα Biologic from Amgen

Fineline Cube Nov 17, 2023

Biotechnology firm Q32 Bio has announced its decision to reclaim full development and commercial rights...

Posts pagination

1 … 485 486 487 … 709

Recent updates

  • AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients
  • Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA
  • Fosun Pharma Launches Phase 2 Trial of FXS7553 DPP‑1 Inhibitor for COPD in China
  • Asieris Pharmaceuticals Wins FDA Clearance for APL‑2501, an Anti‑CLDN6/9 ADC in Advanced Solid Tumors
  • Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Company Drug

Fosun Pharma Launches Phase 2 Trial of FXS7553 DPP‑1 Inhibitor for COPD in China

Company Drug

Asieris Pharmaceuticals Wins FDA Clearance for APL‑2501, an Anti‑CLDN6/9 ADC in Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.